This week brought a flurry of AI developments across biotech, finance, and longevity research. Pfizer said it's reviewing a new molecule designed using artificial intelligence, Anthropic's pre-IPO valuation topped $1 trillion, and two prominent scientists argued that AI offers a credible path to reversing human aging.
Pfizer reviews AI-designed molecule
Pfizer CEO Albert Bourla announced that the company is examining a molecule created with AI. Since 2020, Pfizer has paid up to $350 million to PostEra for AI-designed small molecules and antibody-drug conjugate payloads. In January 2026, Pfizer also struck a strategic collaboration with the team behind the Boltz biomolecular foundation model to refine open-source models using internal data. The move signals a deepening bet on AI to speed up drug development.
Anthropic's trillion-dollar valuation and banking agents
Anthropic's pre-IPO valuation crossed $1 trillion in April 2026, and first-quarter revenue grew roughly 80 times on an annualized basis. The company released Claude Opus 4.7 and a set of new AI agents built for banks, including a financial-crime tool developed with FIS. CEO Dario Amodei said that Chinese AI labs are likely 6 to 12 months behind frontier US capabilities, and that other US labs trail Anthropic by 1 to 3 months.
Meanwhile, Anthropic's Mythos model has surfaced tens of thousands of previously unknown software vulnerabilities. The company warned of a 6 to 12-month patching window, giving organizations a tight timeline to fix flaws before attackers could exploit them.
Reversing aging with AI
Biomedical gerontologist Aubrey de Grey and immunology professor Derya Unutmaz argued that AI is a credible path to reversing aging. Unutmaz predicted that most diseases could be addressed within 10 to 15 years, and said it will soon be malpractice not to use AI in medicine. De Grey estimated a roughly 50% chance of reaching longevity escape velocity — the point where science extends life faster than time passes — by the late 2030s.
The timelines are bold. But for now, the patch clock is ticking on those tens of thousands of vulnerabilities, and regulators are watching how banks deploy AI agents. No one knows which of these frontiers will break first.
